Roche/Ipsen's taspoglutide succeeds in sixth pivotal trial
This article was originally published in Scrip
Executive Summary
Roche and Ipsen's antidiabetic taspoglutide outperformed placebo in the T-emerge 3 trial, the companies report. The success marks the sixth positive Phase III trial for the once-weekly GLP-1 analogue, which previously demonstrated non-inferiority to Sanofi-Aventis's Lantus (insulin glargine) and superiority to Merck & Co's DPP-4 inhibitor Januvia (sitagliptin) and to Amylin/Lilly's GLP-1 mimetic Byetta (exenatide) in some patient populations (scripnews.com, 17 December 2009).